JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus ...Middle East

SHANGHAI, April 10, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that it has received the Investigational New Drug (IND) clearance...

Hence then, the article about jw therapeutics announces ind approval for the clinical trial of relma cel in patients with moderately or severely refractory systemic lupus erythematosus was published today ( Monday 10/04/2023 - 02:32 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus )

Also on site :

• LA28 ticket registration nears deadline as first Olympic qualifiers emerge
• En medio de la crisis, el Gobierno de Cuba anuncia reformas económicas aunque persisten los obstáculos
• What do you need to vote in Illinois? What you can take into the ballot box with you